费城染色体阳性急性淋巴细胞白血病:十个常见问题
本文以十个常见问题形式综述费城染色体阳性急性淋巴细胞白血病(Ph+ ALL)的突破与争议,涉及含酪氨酸激酶抑制剂(TKI)的化疗方案、无化疗方案、可测量残留病监测、异基因造血干细胞移植的取舍、移植后维持治疗及复发后新联合方案与细胞治疗的序贯策略。
要点
- 含第一、二、三代TKI的化疗方案已改善Ph+ ALL患者的分子学缓解和总生存。
- 无化疗方案如贝林妥欧单抗-达沙替尼或贝林妥欧单抗-帕纳替尼展现潜力,但预防中枢神经系统复发仍是挑战。
- 可测量残留病监测是基石,尤其采用二代测序(NGS)-Clonoseq进行准确评估。
核心结论
- 含TKI方案及新型无化疗组合已革新Ph+ ALL患者结局,但围绕移植取舍、移植后维持治疗及复发后方案序贯仍存争议。
研究设计与样本
- 综述,围绕Ph+ ALL十个常见问题汇总突破与争议。
主要发现
- 含第一、二、三代TKI的化疗方案已革新患者结局,包括分子学缓解和总生存。
- 无化疗方案如贝林妥欧单抗-达沙替尼或贝林妥欧单抗-帕纳替尼提供新可能,但预防中枢神经系统复发存在挑战。
- 可测量残留病监测是基石,尤其使用二代测序(NGS)-Clonoseq进行准确评估。
- 关于能否省略异基因造血干细胞移植巩固治疗的争议,与早期分子学缓解患者采用新联合方案获得的优异生存有关,但移植用于第一缓解之外时疾病控制较低。
- 移植后维持治疗中最佳TKI、剂量和疗程仍是未解问题;复发Ph+ ALL使用多种新联合方案和细胞治疗,需明确最佳序贯策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) constitutes a distinctive cytogenetic entity associated with challenging outcomes, particularly in adult patients. Current upfront chemotherapy-tyrosine kinase inhibitor (TKI)-based therapies include first, second and third-generation TKIs that have revolutionized patient outcomes including molecular remission and overall survival. Chemotherapy-free regimens such as blinatumomab-dasatinib or blinatumomab-ponatinib offer exciting possibilities, yet challenges arise, particularly in preventing central nervous system relapse. Monitoring measurable residual disease is now a cornerstone particularly using next-generation sequencing (NGS)-Clonoseq for accurate assessment. Controversy regarding the ability to omit consolidation with allogeneic stem cell transplantation, specifically for patients achieving early molecular remission, is related to the excellent survival achieved with novel combinations in the upfront setting, however challenged by the lower disease control when transplant is utilized beyond first remission. Post-transplant maintenance introduces new dilemmas: the optimal TKI, dosing, and duration of therapy are open questions. Meanwhile, a myriad of new combinations and cellular therapies are used for relapsed Ph+ ALL, prompting us to unravel the optimal sequencing of these promising regimen. In this review, we delve into the breakthroughs and controversies in Ph+ ALL with ten commonly asked questions.
引用
- Abou Dalle I, Moukalled N, El Cheikh J, et al. Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions. Leukemia. 2024. PMID: 38902471. doi:10.1038/s41375-024-02319-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。